ZYBERNO
Stock Report
Updated Sep 1, 2026

Aktis Oncology, Inc. (AKTS)

Healthcare • NASDAQ

$25.78

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
Aktis Oncology, Inc. (AKTS) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.04x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-215.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Aktis Oncology, Inc. (AKTS) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:25.78
Market Cap:$1.43B

Valuation Multiples (2)

P/B Ratio:2.94x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$919.58M

Price Action & Momentum (1)

% of 52-Week High:75.4%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-4.4%
Fundamental Growth Rate (g):9.5%

Margin Analysis (1)

Ebitda Margin:-827.4%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:16.33x
Quick Ratio:16.33x
Cash Ratio:16.10x

Leverage Analysis (3)

Debt To Equity Ttm:0.04x
Debt-to-Equity Ratio:0.04x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:492,411,000.00
Cash And Cash Equivalents:517,300,000.00
Long Term Debt:$9.76M
Net Debt:-$506.06M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$13.54M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$115.60M

Bottom Line Performance (3)

-$96.58M
Income Before Tax:$0.00
Ebitda Ttm:-111,996,000.00

Operating Expenses (5)

Operating Expenses:32,283,000.00
R And D Expense:25,280,000.00
Sga Expense:7,003,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:747.0%
Sga To Revenue Percentage:206.9%
Ebitda Margin:-827.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$557.60M
Current Assets:$524.54M
Ppe Net:15,966,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:72,758,000.00
Current Liabilities:32,128,000.00
Long Term Debt:$9.76M
Short Term Debt:$1.48M

Equity & Capital (3)

Equity:$484.84M
Retained Earnings:-$199.03M
Common Stock:480,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:10,778,000.00

Special Items (2)

Contract Liabilities:17,339,000.00
Stock Based Compensation:3,222,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$96.97M-$104.38M

Investment Activities (1)

Investing Cash Flow:$20.54M

Financing Activities (3)

Financing Cash Flow:$337.55M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:5,376,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$1.75

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.24
Operating Cash Flow Per Share:-$1.75

Book Value & Capital (2)

Book Value Per Share:$8.77
Cash Per Share:9.35

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:0.03x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:290.63
Cash Conversion Cycle:-2,288.63
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-4.4%
Fundamental Growth Rate (g):9.5%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:AKTS
Company Name:Aktis Oncology, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:55.30M
Shares Outstanding Basic:55.30M
Shares Outstanding Diluted:55.30M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 02:23:47 UTC
Data Timestamp:2026-09-01T02:23:47.454309
Scroll to Top